% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Palleis:285043,
      author       = {Palleis, Carla and Bernhardt, Alexander Maximilian and
                      Weidinger, Endy and Fietzek, Urban M and Jäck, Alexander
                      and Katzdobler, Sabrina and Gnoerich, Johannes and Bauer,
                      Theresa and Franzmeier, Nicolai and Perneczky, Robert and
                      Brendel, Matthias and Levin, Johannes and Höglinger,
                      Günter U},
      collaboration = {Tauopathies, German Imaging Initiative for},
      title        = {{A} {B}iomarker-{B}ased {C}lassification of {C}orticobasal
                      {S}yndrome.},
      journal      = {Movement disorders},
      volume       = {41},
      number       = {1},
      issn         = {0885-3185},
      address      = {New York, NY},
      publisher    = {Wiley},
      reportid     = {DZNE-2026-00167},
      pages        = {129 - 142},
      year         = {2026},
      abstract     = {Corticobasal syndrome (CBS) is a clinically defined
                      syndrome with progressive movement and cortical dysfunction,
                      caused by various underlying pathologies, most commonly
                      tau-predominant pathologies such as progressive supranuclear
                      palsy and corticobasal degeneration, or Alzheimer's disease
                      (AD). Lewy-type α-synucleinopathies (LTS), TDP-43
                      proteinopathies, and mixed pathologies may also underlie
                      CBS. The clinical impact of these pathologies remains poorly
                      understood.To subclassify CBS patients in vivo using
                      biomarkers for amyloid-β (Aβ), Tau, and α-synuclein
                      (αSyn), and assess the clinical relevance of this
                      stratification.We conducted a prospective cohort study of 50
                      CBS patients at LMU University Hospital Munich. Biomarker
                      analysis included cerebrospinal fluid (CSF) Aβ42 and
                      Aβ42/40, [18F]flutemetamol Aβ-PET, [18F]PI-2620 tau-PET,
                      and αSyn seed amplification assays in CSF. CSF
                      neurofilament light chain (NfL) served as a marker of
                      neurodegeneration. Patients were stratified into six groups
                      based on biomarker positivity.Tau positivity was found in
                      $90\%$ of CBS cases, Aβ in $28\%,$ and αSyn in $24\%.$
                      Stratification identified: $52\%$ consistent with
                      tau-predominant pathology, $18\%$ with AD, $10\%$ with
                      AD+LTS, $10\%$ with tau-predominant+LTS, $4\%$ with isolated
                      LTS, and $6\%$ unclassified. αSyn positivity was more
                      frequent in AD-CBS $(36\%)$ than in tau-predominant-CBS
                      $(16\%).$ Aβ-positive cases showed greater cognitive
                      impairment; Tau positivity correlated with worse motor
                      symptoms; αSyn-positive patients had milder motor symptoms,
                      slower progression, and lower NfL levels.CBS is molecularly
                      heterogeneous. Biomarker-based classification may enhance
                      diagnostic precision and support personalized therapeutic
                      strategies. © 2025 The Author(s). Movement Disorders
                      published by Wiley Periodicals LLC on behalf of
                      International Parkinson and Movement Disorder Society.},
      keywords     = {Humans / Male / Female / Aged / Biomarkers: cerebrospinal
                      fluid / Amyloid beta-Peptides: cerebrospinal fluid / Middle
                      Aged / tau Proteins: cerebrospinal fluid / Positron-Emission
                      Tomography / alpha-Synuclein: cerebrospinal fluid /
                      alpha-Synuclein: metabolism / Prospective Studies /
                      Corticobasal Degeneration: classification / Corticobasal
                      Degeneration: cerebrospinal fluid / Corticobasal
                      Degeneration: diagnostic imaging / Peptide Fragments:
                      cerebrospinal fluid / Aged, 80 and over / proteinopathies
                      (Other) / tau‐PET (Other) / α‐synuclein seed
                      amplification assay (Other) / β‐amyloid (Other) /
                      Biomarkers (NLM Chemicals) / Amyloid beta-Peptides (NLM
                      Chemicals) / tau Proteins (NLM Chemicals) / alpha-Synuclein
                      (NLM Chemicals) / Peptide Fragments (NLM Chemicals) /
                      amyloid beta-protein (1-42) (NLM Chemicals)},
      cin          = {Clinical Research (Munich) / AG Levin / AG Haass / AG
                      Dichgans},
      ddc          = {610},
      cid          = {I:(DE-2719)1111015 / I:(DE-2719)1111016 /
                      I:(DE-2719)1110007 / I:(DE-2719)5000022},
      pnm          = {353 - Clinical and Health Care Research (POF4-353) / 352 -
                      Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41048081},
      pmc          = {pmc:PMC12882055},
      doi          = {10.1002/mds.70070},
      url          = {https://pub.dzne.de/record/285043},
}